Discern Health

News

W2O has bought US health economics and outcomes research company Discern Health, marking its sixth acquisition in less than a year.

News

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.